Weight-Loss Drug Shows Promise in Reducing Sleep Apnea

An experimental weight-loss drug significantly reduced episodes of interrupted breathing during sleep in two clinical studies involving people with obesity or excess weight.

The findings point to a potential new approach to sleep apnea, a common disorder in which breathing repeatedly stops and starts during the night.

Although snoring can be a sign of sleep apnea, the two are not interchangeable. The reported improvement concerned interruptions in breathing, rather than snoring alone.

The results suggest that a treatment developed for weight loss could also have a role in managing sleep-related breathing problems. However, the available summary does not establish whether the benefit came from weight loss itself or another effect of the drug.

The findings are promising, but they do not mean weight-loss injections are an established treatment for everyone who snores. Further details are needed to assess the experimental drug’s safety, suitability and lasting effects.